biostudies-literatureWeir ACancer Research UKNCATS NIH HHSNCRR NIH HHSMedical Research CouncilNCI NIH HHS137-147https://www.ebi.ac.uk/biostudies/studies/S-EPMC9814937biostudies-literatureUnknown128(1)<h4>Background</h4>Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC.<h4>Methods</h4>Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) repBritish journal of cancerIncreased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.PMC981493716561U01 CA164973A15601UL1 TR000124K07 CA080668UL1 TR001881C490/A16561R01 CA168758R01 CA160669P30 CA047904R01 CA172404R01 CA122443P50 CA136393R01 CA248288R01 CA087538P30 CA015083R01 CA058598M01 RR000056R01 CA095023A22905MC_UU_00004/01A17197R01 CA112523Shah MKobel MHarnett PRBoros JLubinski JFord CEGronwald JGentry-Maharaj AAlsop JShvetsov YBStaebler ABerger JKelemen LEOrsulic SLester JRyan AHarnett PFischer AModugno FKoziak JMJimenez-Linan MHein AKarlan BYHeublein SMeagher NSVierkant RATalhouk ABenitez JSteed HHendley JNey BHuntsman DGSchildkraut JMCushing-Haugen KLCandido Dos Reis FJKraemer BRiggan MJGarcia MJHuzarski TOlawaiye AGoodman MTWilkens LRBowtell DDLee CHHuang YGrube MTaylor SECybulski CErber RTraficante NKennedy CJWang CAOCs groupBisinotto CPharoah PDPWinham SJMenkiszak JSingh NSinn HPSharma RFereday SBrand AFasching PANelson GSWidschwendter MCarney MEHernandez BYKommoss FKFBrooks-Wilson ABerchuck ABowtell DLe NDCook LSDoherty JAGilks BCWeir AGhatage PMenon UBrand AHKommoss SBeckmann MWLesnock JRamus SJCunningham JMHarris HRDeFazio APaz-Ares LOsorio ARobles-Diaz LHartmann ARuebner MBrenton JDGayarre JElishaev EKang EYAnglesio MSJakubowska AGoode ELfalseIncreased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.<h4>Background</h4>Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC.<h4>Methods</h4>Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) rep2023-01-01T00:00:00Z2023 Jan2026-05-29T20:15:42.145Z2025-04-04T12:37:31.076ZS-EPMC98149373632387810.1038/s41416-022-02014-y